Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

National Survey on Coronary Patients and Heart Failure Performed in 2 Patient Groups (COMPAR)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00699959
First received: June 16, 2008
Last updated: August 4, 2009
Last verified: August 2009
  Purpose

The purpose of this observational study is to compare frequency of attainment control goals through the more represented cardiovascular factor risk, dyslipidemia, among coronary patients with or without heart failure in cardiology consulting.


Condition
Coronary Patients
Heart Failure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Comparison and Description of Coronary Patients Management With or Without Heart Failure in Cardiology Consulting

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Frequency of attainment control goals through the more represented cardiovascular factor risk, dyslipidemia, among coronary patients with or without heart failure in cardiology consulting. [ Time Frame: Once ] [ Designated as safety issue: No ]

Enrollment: 1650
Study Start Date: June 2008
Study Completion Date: January 2009
Groups/Cohorts
1
patients with heart failure
2
patients without heart failure

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

First two consecutive Coronary patients with or without heart failure

Criteria

Inclusion Criteria:

  • patient with coronary disease diagnosed since at least 1 year
  • Echocardiography done less than 1 year ago
  • patient with or without documented heart failure

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00699959

  Show 343 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00699959     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2007/8
Study First Received: June 16, 2008
Last Updated: August 4, 2009
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Coronary patients
heart failure
dyslipidemia

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases

ClinicalTrials.gov processed this record on November 20, 2014